August 5, 2025

Efficacy of preoperative 0.1% topical nepafenac in the prevention of cystoid macular edema after cataract surgery in diabetic patients.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This trial demonstrates reduced central macular thickness in diabetic patients after cataract surgery, highlighting topical nepafenac's efficacy.

TOPICAL NEPAFENAC showed a significant reduction in central macular thickness in diabetic patients post cataract surgery.
The PREOPERATIVE administration resulted in a mean central macular thickness of 241.10 µm, compared to 249.31 µm in the control group.
Ninety-six diabetic patients were evaluated for efficacy over three months following cataract surgery.
Overall EFFICACY was recorded at 93.8% for the nepafenac group, indicating its potential role in preventing cystoid macular edema.

Sultan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This trial demonstrates reduced central macular thickness in diabetic patients after cataract surgery, highlighting topical nepafenac's efficacy.